Randomized Study of GLP-1 Drug Effectiveness With Different Monitoring Approaches
Randomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness found specific strategies that optimize treatment outcomes.
Quick Facts
What This Study Found
Randomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness found specific strategies that optimize treatment outcomes.
Key Numbers
105 participants total (52 immediate start, 53 staggered start). Rimegepant 75 mg once daily as orally disintegrating tablet.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Randomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.
- Published In:
- Cephalalgia : an international journal of headache, 45(7), 3331024251355947 (2025)
- Authors:
- Alsaadi, Taoufik(3), Suliman, Reem(3), Yang, Jiyue, Agarwal, Ekta, Fullerton, Terence, Chou, Denise E, Whalen, Ed, El Jadam, Caline, Al Qaisi, Ibrahim, Amin, Youssef, Alkhateri, Athra, Alsaffarini, Kareem, Abraham, Lucy, Zunaed, Zahra, Ahmed, Haytham M, Fathy, Mohamed, Hegab, Mohamed, Vainstein, Nora
- Database ID:
- RPEP-09903
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Randomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness found specific strategies that optimize treatment outcomes.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09903APA
Alsaadi, Taoufik; Suliman, Reem; Yang, Jiyue; Agarwal, Ekta; Fullerton, Terence; Chou, Denise E; Whalen, Ed; El Jadam, Caline; Al Qaisi, Ibrahim; Amin, Youssef; Alkhateri, Athra; Alsaffarini, Kareem; Abraham, Lucy; Zunaed, Zahra; Ahmed, Haytham M; Fathy, Mohamed; Hegab, Mohamed; Vainstein, Nora. (2025). A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.. Cephalalgia : an international journal of headache, 45(7), 3331024251355947. https://doi.org/10.1177/03331024251355947
MLA
Alsaadi, Taoufik, et al. "A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.." Cephalalgia : an international journal of headache, 2025. https://doi.org/10.1177/03331024251355947
RethinkPeptides
RethinkPeptides Research Database. "A randomized open-label study to evaluate the effectiveness ..." RPEP-09903. Retrieved from https://rethinkpeptides.com/research/alsaadi-2025-a-randomized-openlabel-study
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.